IL146659A0 - Porous drug matrices and method of manufacture thereof - Google Patents

Porous drug matrices and method of manufacture thereof

Info

Publication number
IL146659A0
IL146659A0 IL14665900A IL14665900A IL146659A0 IL 146659 A0 IL146659 A0 IL 146659A0 IL 14665900 A IL14665900 A IL 14665900A IL 14665900 A IL14665900 A IL 14665900A IL 146659 A0 IL146659 A0 IL 146659A0
Authority
IL
Israel
Prior art keywords
drug
porous matrix
forming agent
pore forming
volatile
Prior art date
Application number
IL14665900A
Other languages
English (en)
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146659(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/433,486 external-priority patent/US6395300B1/en
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of IL146659A0 publication Critical patent/IL146659A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
IL14665900A 1999-05-27 2000-05-25 Porous drug matrices and method of manufacture thereof IL146659A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13632399P 1999-05-27 1999-05-27
US15865999P 1999-10-08 1999-10-08
US09/433,486 US6395300B1 (en) 1999-05-27 1999-11-04 Porous drug matrices and methods of manufacture thereof
US18631000P 2000-03-02 2000-03-02
PCT/US2000/014578 WO2000072827A2 (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof

Publications (1)

Publication Number Publication Date
IL146659A0 true IL146659A0 (en) 2002-07-25

Family

ID=27495210

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14665900A IL146659A0 (en) 1999-05-27 2000-05-25 Porous drug matrices and method of manufacture thereof
IL146659A IL146659A (en) 1999-05-27 2001-11-21 Methods for preparing a porous matrix of drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146659A IL146659A (en) 1999-05-27 2001-11-21 Methods for preparing a porous matrix of drug

Country Status (18)

Country Link
EP (1) EP1180020B2 (da)
JP (1) JP4722295B2 (da)
KR (2) KR100752000B1 (da)
CN (1) CN1240373C (da)
AT (1) ATE312601T1 (da)
AU (1) AU768022B2 (da)
BR (1) BR0010984A (da)
CA (1) CA2371836C (da)
DE (1) DE60024811T3 (da)
DK (1) DK1180020T4 (da)
ES (1) ES2250141T5 (da)
HK (2) HK1048956B (da)
IL (2) IL146659A0 (da)
MX (1) MXPA01012106A (da)
NO (1) NO323761B1 (da)
NZ (1) NZ516083A (da)
TW (1) TWI274589B (da)
WO (1) WO2000072827A2 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
DE60039132D1 (de) 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10059020A1 (de) * 2000-11-28 2002-05-29 Gruenenthal Gmbh Parenteral applizierbare Darreichungsformen
KR100743404B1 (ko) 2000-12-21 2007-07-30 넥타르 테라퓨틱스 폴리엔 항균제의 폐 전달
JP2004520398A (ja) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PT1360169E (pt) † 2001-02-12 2007-10-29 Wyeth Corp Sal succinato de o-desmetil-venlafaxina
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7105178B2 (en) 2001-07-17 2006-09-12 Sun Pharmaceutical Industries Limited Cardiotonic composition
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
WO2003079992A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Pulmonary delivery for levodopa
JP4452970B2 (ja) * 2002-03-27 2010-04-21 日本臓器製薬株式会社 ジクロフェナクナトリウム経口製剤
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
GB0401947D0 (en) 2004-01-28 2004-03-03 Unilever Plc Porous bodies and method of production thereof
KR100681660B1 (ko) * 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
WO2007004236A2 (en) * 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US20100226990A1 (en) * 2006-01-27 2010-09-09 The Provost, Fellows And Scholars Of The College O Method of Producing Porous Microparticles
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
RU2463079C2 (ru) 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
PT103743B (pt) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A Processo para preparar derivados de 21-disódio fosfato de pregnanos.
WO2009027644A2 (en) 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
AU2008311053B2 (en) * 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
CA2767560A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um
EP2328555A2 (en) * 2008-08-22 2011-06-08 Slotervaart Participaties BV Compositions for the treatment of neoplastic diseases
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
PT2611529T (pt) 2010-09-03 2019-05-09 Bend Res Inc Método de secagem por pulverização
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
CN103301095B (zh) * 2012-03-13 2016-04-13 中国科学院上海药物研究所 一种用于提高普罗布考口服吸收的多孔复合载药组合物及其制备方法
US20150150788A1 (en) * 2012-06-22 2015-06-04 The University Of Queensland Method and composition for delivering a compound through a biological barrier
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL3154528T3 (pl) * 2014-06-11 2023-07-10 SpecGx LLC Suszone rozpyłowo kompozycje o różnych profilach rozpuszczania i sposoby ich wytwarzania
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
AU2015364280A1 (en) * 2014-12-18 2017-07-06 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
RU2750163C2 (ru) * 2015-06-04 2021-06-22 Крититек, Инк. Таксановые частицы и их применение
BR112018005200A2 (pt) 2015-09-16 2018-10-09 Dfb Soria Llc liberação de nanopartículas de fármaco e métodos de uso dos mesmos
RU2737934C2 (ru) 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101965708B1 (ko) * 2016-08-30 2019-04-04 이화여자대학교 산학협력단 스폰지 유사 구조를 갖는 고분자 미립자 및 이의 제조방법
CN110636833A (zh) 2017-03-15 2019-12-31 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CN111278436A (zh) 2017-10-03 2020-06-12 克里蒂泰克公司 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
WO2019178024A1 (en) 2018-03-16 2019-09-19 Dfb Soria, Llc Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes
AU2020216278A1 (en) * 2019-01-29 2021-07-15 Bayer Healthcare Llc Topical gel compositions of naproxen
CN114269816B (zh) * 2019-05-10 2023-09-19 阿诺米拉公司 多孔纤维素微粒及其制备方法
EP4037666B1 (en) 2020-12-08 2024-05-01 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
CN113081971A (zh) * 2021-05-14 2021-07-09 江西中医药大学 一种中药多孔核壳型复合粒子粉体及其制备方法和应用
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1265615A (da) * 1970-09-10 1972-03-01
NL7313626A (nl) † 1973-10-04 1975-04-08 Philips Nv Gecombineerde inrichting voor het produceren en sselen van warmte met een warmte ver- ende inrichting.
GB8322007D0 (en) † 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
IL82245A (en) * 1986-04-25 1990-07-26 Basf Ag Preparation of spray-dried granules of active ingredients
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
PT954282E (pt) † 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
JP2001517692A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
JP4758525B2 (ja) * 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery

Also Published As

Publication number Publication date
NO323761B1 (no) 2007-07-02
JP2003500438A (ja) 2003-01-07
DK1180020T3 (da) 2006-03-27
DE60024811T3 (de) 2010-01-07
EP1180020B2 (en) 2009-06-24
WO2000072827A9 (en) 2002-01-31
ES2250141T5 (es) 2009-11-05
CN1240373C (zh) 2006-02-08
KR100883477B1 (ko) 2009-02-16
KR20020011992A (ko) 2002-02-09
DE60024811D1 (de) 2006-01-19
CA2371836A1 (en) 2000-12-07
CA2371836C (en) 2006-01-31
NO20015753L (no) 2002-01-28
DK1180020T4 (da) 2009-10-05
ATE312601T1 (de) 2005-12-15
BR0010984A (pt) 2002-04-30
CN1365274A (zh) 2002-08-21
HK1094775A1 (en) 2007-04-13
AU768022B2 (en) 2003-11-27
EP1180020B1 (en) 2005-12-14
NZ516083A (en) 2003-08-29
WO2000072827A2 (en) 2000-12-07
MXPA01012106A (es) 2003-06-30
KR20070069219A (ko) 2007-07-02
EP1180020A2 (en) 2002-02-20
WO2000072827A3 (en) 2001-01-25
ES2250141T3 (es) 2006-04-16
TWI274589B (en) 2007-03-01
JP4722295B2 (ja) 2011-07-13
HK1048956A1 (en) 2003-04-25
KR100752000B1 (ko) 2007-08-28
NO20015753D0 (no) 2001-11-26
HK1048956B (zh) 2006-07-28
IL146659A (en) 2010-05-31
AU5445900A (en) 2000-12-18
DE60024811T2 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
IL146659A0 (en) Porous drug matrices and method of manufacture thereof
CA2430288C (en) A composition improved in the solubility or oral absorbability
WO2001095877A3 (en) Porous celecoxib matrices and methods of manufacture thereof
JP2000229846A (ja) 放出制御型剤形
ATE77946T1 (de) Injizierbares langwirkendes mikroteilchenpr|parat zur verabreichung entzuendungshemmender mittel.
EP1295595A4 (en) TABLET RAPIDLY DISINTEGRATING IN THE MOUTH AND CORRESPONDING PRODUCTION PROCESS
JPS58116414A (ja) ニカルジピン持続性製剤用球形顆粒およびその製造法
JP4401778B2 (ja) 超臨界流体を用いて活性物質と多孔質支持体とを相互反応させた物質の製造方法
AU2003235156B2 (en) Solid dispersion composition
TH78112B (th) เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น
TH78112A (th) เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น
Minocha et al. SOlubility enhancement of poorly water soluble drugs by various techniques
EP0323762B1 (fr) Nouvelles compositions anti-tussives et leur procédé d'obtention
KR100981750B1 (ko) 분무-건조 과립 및 그의 제조방법
JP2616946B2 (ja) 肝類洞小孔拡張・増加剤
OGiso et al. ABSORPTION AND BIOAVAILABILITY OF CALCIUM AND MAGNESIUM SALTS OF INDOMETHACIN FROM RECTAL SUPPOSITO-RIES
CN104887722A (zh) 溶解性和安全性增强的银杏达莫注射剂及制备方法和应用
JP2005298472A (ja) イトラコナゾールを含む経口投与用組成物
JP5691142B2 (ja) ベンズイミダゾール系注射剤
JPH07291863A (ja) 腎保護作用剤
Harindran ENHANCEMENT OF BIOA DIFFERENT SOLUBILIT TECHNIQUES